Authors


Kim Papp, MD, PhD, FRCPC

Latest:

Kim Papp, MD, PhD, FRCPC: Exploring the Potential of ESK-001 in Plaque Psoriasis

Papp shared insights from the recent STRIDE phase 2 trial, which met all its primary and secondary endpoints. Data was presented at the American Academy of Dermatology Annual Meeting.


James Song, MD, FAAD

Latest:

Balancing Safety and Efficacy With Key Data

James Song, MD, discusses how clinical trial data demonstrates the risk-benefit profile of vitiligo therapies, with particular focus on balancing potential adverse effects of Janus kinase inhibitors against their proven efficacy in achieving repigmentation.


Stella Kyaw-Soe, PharmD, MBA, Sanofi, Cambridge, USA

Latest:

OX40-Ligand: A Conductor of the Atopic Dermatitis Inflammatory Symphony?

Given the complexity of the underlying inflammation in patients with AD, an increased understanding of the OX40L pathway can improve our understanding of AD pathogenesis.


Iltefat Hamzavi, MD

Latest:

Potential Role of AI in HS Diagnosis

Panelists discuss how the role of AI in Hidradenitis Suppurativa and the potential for complex multi-input factors.


Marian Freedman

Latest:

Does diet really play a role in acne?

For years, teenagers have been told to avoid certain foods to reduce acne. A review article examines the evidence.



Peter Baek

Latest:

An Overview of Argyria

Argyria is a rare dermatologic condition that presents with blue or grey mucocutaneous discoloration following cutaneous exposure or ingestion of silver.


Matthew Reynolds, PA-C

Latest:

Managing aBCC and aCSCC With Cemiplimab: Tips From Matthew Reynolds, PA-C

Reynolds discussed what attendees need to know about using cemiplimab to target their difficult skin cancer patients at the Fall Clinical Dermatology Conference for PAs and NPs.



Robert J. Casquejo, PA-C

Latest:

Clinical Challenges in Treating Atopic Dermatitis

Panelists discuss how managing atopic dermatitis presents complex clinical challenges, including treatment resistance, medication adherence, identifying triggers, and tailoring therapies to individual patient needs and disease severity.


Melinda Gooderham, MSc, MD, FRCPC

Latest:

Phase 2b Trial Reinforces Zasocitinib’s Safety Profile

Melinda Gooderham, MSc, MD, FRCPC, emphasized the significance of the study’s results, showcasing stable laboratory parameters over a 12-week trial.


Eileen Cheever, MPAS, PA-C

Latest:

“Is AI Coming for My Job?”: Familiarizing Clinicians with AI Tools and Their Role in Dermatology

In a session at Elevate-Derm West, Cheever presented on the utilization of AI within dermatology to optimize patient communication and diversify research.


Jeremy D. Sherer, JD

Latest:

Telehealth in 2023: What Physicians Need to Know

Answers to some common questions about providing telehealth services in 2023.


Adelaide A. Hebert, MD, FAAD

Latest:

Final Thoughts on Tapinarof in AD Clinical Trials

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, review the study results for the ADORING 1 and ADORING 2 trials, as well as share closing thoughts on the use of tapinarof in management of AD.


Glynis Ablon, MD

Latest:

Glynis Ablon, MD, Spotlights Top Devices and Innovations in Aesthetic Dermatology

At Fall Clinical 2024, Ablon shared her top device-based interventions, from wound care to radiofrequency rejuvenation, revealing clinical pearls for enhanced aesthetic outcomes.


Joel M. Gelfand, MD, MSCE, FAAD

Latest:

Exploring Advancements in Palmoplantar Pustulosis, Psoriasis Comorbidities, and Phototherapy

Joel Gelfand, MD, discusses insights on complex psoriasis cases, comorbidity management, and the evolving role of phototherapy at Fall Clinical 2024.


Heidi Anne Duerr, MPH

Latest:

Test Your Knowledge: Acne Pearls From SDPA

Take this quiz to see if you are leveraging the latest research in acne treatment.



Karan Lal, DO, MS, FAAD

Latest:

Engaging Parents, Caregivers, and Schools in the Management of Pediatric Atopic Dermatitis

Karan Lal, DO, MS, FAAD, discusses how building a collaborative care network between parents, caregivers, and school staff is crucial for successful management of pediatric atopic dermatitis through consistent treatment application, trigger avoidance, and emergency response planning.


Kassim Rahawi, PharmD, Sanofi, Cambridge, USA

Latest:

OX40-Ligand: A Conductor of the Atopic Dermatitis Inflammatory Symphony?

Given the complexity of the underlying inflammation in patients with AD, an increased understanding of the OX40L pathway can improve our understanding of AD pathogenesis.


Bob Rhatigan

Latest:

Expanding Innovation and Education in Medical Aesthetics

Bob Rhatigan, CEO of Merz Aesthetics, discusses the organization’s commitment to advancing the aesthetics industry through strategic partnerships, specialized training, and a growing portfolio of injectables and devices.


Jonathan S Zager, MD, FACS, FSSO

Latest:

Expert Perspectives on BOLT clinical trial data

John Strasswimmer, MD, PhD comments on the impressive utility of both vismodegib and sonidegib in patients with advanced basal cell carcinoma and Jonathan S Zager, MD, FACS, FSSO provides his insight into the clinical utility of both of these treatments.


Nathalie Ly

Latest:

Considerations to Best Serve Transgender Patients Seeking Aesthetic Care

Ronda Farah, MD, and her colleagues reviewed how dermatology providers play an important role in transgender aesthetic care.


Benjamin Lockshin, MD, FAAD

Latest:

Patient Education and Novel Topical Therapies for AD

Panelists discuss how age restrictions for PDE4 inhibitors affect treatment decisions for pediatric patients with atopic dermatitis, addressing parental concerns and highlighting the benefits of a single treatment option like roflumilast for managing overlapping inflammatory dermatologic conditions; they also explore current guidelines for corticosteroid use, the potential impact of PDE4 inhibitors on these guidelines, and the future of topical PDE4 inhibitors in dermatology, including the integration of new agents into treatment paradigms and key considerations for patient education and decision-making.


Martin Zaiac, MD

Latest:

Beyond Aesthetics: The Vital Role of Nails in Health

Martin Zaiac, MD, gave insight on potential risks associated with manipulation of nails, hygiene, and when it is necessary to see a specialist.


Hilary Baldwin, MD

Latest:

Advances and Challenges in Rosacea Treatment: Insights From Hilary Baldwin, MD

At the 2024 SDPA Fall Conference, Hilary Baldwin, MD, highlighted innovative strategies for managing complex rosacea cases, the importance of combination approaches, and a slowing treatment pipeline.


Courtney Marabella

Latest:

Topical Remetinostat Effective, Tolerable in Basal Cell Carcinoma

The topical HDAC inhibitor remetinostat demonstrated favorable tolerability and clinically significant efficacy in reducing disease burden in patients with basal cell carcinoma, according to results from a phase 2 trial.


Adam Braunscheidel, CFP

Latest:

Residency Is Ending Soon: Key Financial Tips for Your Next Chapter

From a financial perspective, the change from resident to attending dermatologist may be profound.


Elizabeth Swanson, MD

Latest:

Enhancing Atopic Dermatitis Treatment: Insights From Cutting-Edge Studies and Clinical Perspectives Part 3

A 5-expert panel continues their conversation on atopic dermatitis, discussing patient-centered care and key takeaways.


Maryanne Makredes Senna, MD

Latest:

Navigating Challenges and Advancements in Alopecia Areata Treatment

Maryanne Makredes Senna, MD, shares insights into the complexities of treating alopecia areata and guidance for clinicians.

© 2024 MJH Life Sciences

All rights reserved.